Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study

Journal of Affective Disorders

Volumn 128, Issue 1-2, 2011, Pages 83-94

  Bortnick, Brian ^a   El Khalili, Nizar ^b   Banov, Michael ^c   Adson, David ^d   Datto, Catherine ^e   Raines, Shane ^e   Earley, Willie ^e   Eriksson, Hans ^f  

^a Comprehensive Neuroscience ^*  (United States)

^b Alpine Clinic   (United States)

^c BEHAVIORAL RESEARCH CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e ASTRAZENECA   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

Depression; Major depressive disorder; Monotherapy; Once daily; Quetiapine

Indexed keywords

PLACEBO; QUETIAPINE;

ADULT; AKATHISIA; APPETITE; ARTICLE; AUTOMUTILATION; BODY WEIGHT; CHILL; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSOMNIA; LASSITUDE; LETHARGY; LIBIDO; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NOSE CONGESTION; PARALLEL DESIGN; PESSIMISM; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE; SWEATING; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VAGINAL DRYNESS; VITAL SIGN; VULVOVAGINAL DRYNESS; XEROSTOMIA;

EID: 78649676124     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2010.06.031     Document Type: Article

References (56)

1. D.E. Adson, M.G. Kushner, K.M. Eiben, and S.C. Schulz Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors Depress. Anxiety 19 2004 121 126
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th Edition 1994 American Psychiatric Association Washington, DC
3. I.M. Anderson Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability J. Affect. Disord. 58 2000 19 36
4. T.R. Barnes A rating scale for drug-induced akathisia Br. J. Psychiatry 154 1989 672 676
5. M. Bauer, H. Pretorius, E. Constant, W. Earley, J. Szamosi, and M. Brecher Extended release quetiapine fumarate as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study J. Clin. Psychiatry 70 2009 540 549
6. R.M. Berman, R.N. Marcus, R. Swanink, R.D. McQuade, W.H. Carson, P.K. Corey-Lisle, and A. Khan The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study J. Clin. Psychiatry 68 2007 843 853
7. R.M. Berman, R.N. Marcus, R. Swanink, R.D. McQuade, W.H. Carson, P.K. Corey-Lisle, and A. Khan The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study J. Clin. Psychiatry 68 2007 843 853
8. G.W. Blair-West, G.W. Mellsop, and M.L. Eyeson-Annan Down-rating lifetime suicide risk in major depression Acta Psychiatr. Scand. 95 1997 259 263
9. D.J. Buysse, C.F. Reynolds III, T.H. Monk, S.R. Berman, and D.J. Kupfer The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research Psychiatry Res. 28 1989 193 213
10. J.R. Calabrese, P.E. Keck Jr., W. Macfadden, M. Minkwitz, T.A. Ketter, R.H. Weisler, A.J. Cutler, R.N. McCoy, E. Wilson, J. Mullen BOLDER Study Group A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression Am. J. Psychiatry 162 2005 1351 1360
11. A.H. Clayton, E.L. McGarvey, and G.J. Clavet The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity Psychopharmacol. Bull. 33 1997 731 745
12. A. Cutler, C. Datto, A. Nordenhem, M. Minkwitz, B. Dettore, L. Acevedo, and D. Darko Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar mania Poster presented at the 161st Annual Meeting of the American Psychiatric Association, Washington, DC, USA, May 3 - 8 2008
13. A. Cutler, S. Montgomery, D. Feifel, A. Lazarus, M. Åström, and M. Brecher Extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study J. Clin. Psychiatry 70 2009 526 539
14. C. Datto, L. Berggren, J. Patel, and H.A. Eriksson Self-Reported Sedation Profile of Immediate-Release Quetiapine Fumarate Compared With Extended-Release Quetiapine Fumarate During Dose Initiation: A Randomized, Double-Blind, Crossover Study in Healthy Adult Subjects Clin. Ther. 31 2009 492 502
15. J. Davis, R.Y. Fujimoto, D.T. Juarez, K.A. Hodges, and J.K. Asam Major depression associated with rates of cardiovascular disease state transitions Am. J. Manag. Care 14 2008 125 128
16. J.P. Doree, R.J. Des, V. Lew, A. Gendron, R. Elie, E. Stip, and S.V. Tourjman Quetiapine augmentation of treatment-resistant depression: a comparison with lithium Curr. Med. Res. Opin. 23 2007 333 341
17. N. El-Khalili, M. Joyce, M. Atkinson, R. Buynak, C. Datto, P. Lindgren, and H. Eriksson Extended release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment - a multicenter, randomized, double-blind, placebo-controlled study Int. J. Neuropsychopharmacol. 23 2010 1 16 Feb [Epub ahead of print]
18. EMEA Note for guidance on clinical investigation of medicinal products in the treatment of depression 2002 Available at: http://www.emea.europa.eu/pdfs/ human/ewp/051897en.pdf
19. J. Endicott, J. Nee, W. Harrison, and R. Blumenthal Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure Psychopharmacol. Bull. 29 1993 321 326
20. M. Fava, and K.G. Davidson Definition and epidemiology of treatment-resistant depression Psychiatr. Clin. North. Am. 19 1996 179 200
21. C. Figueroa, M. Brecher, J.E. Hamer-Maansson, and H. Winter Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release Prog. Neuropsychopharmacol. Biol. Psychiatry 33 2009 199 204
22. J.M. Goldstein, S. Nyberg, and M. Brecher Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant and mood stabilizing properties of Seroquel Eur. Psychiatry 23 Suppl 2 2008 S202
23. R.S. Gregorian, K.A. Golden, A. Bahce, C. Goodman, W.J. Kwong, and Z.M. Khan Antidepressant-induced sexual dysfunction Ann. Pharmacother. 36 2002 1577 1589
24. M. Hamilton The assessment of anxiety states by rating Br. J. Med. Psychol. 32 1959 50 55
25. M. Hamilton A rating scale for depression J. Neurol. Neurosurg. Psychiatry 23 1960 56 62
26. N.H. Jensen, R.M. Rodriguiz, M.G. Caron, W.C. Wetsel, R.B. Rothman, and B.L. Roth N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT(1A) Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity Neuropsychopharmacology 33 2008 2303 2312
27. R.S. Kahn, S.C. Schulz, V.D. Palazov, E.B. Reyes, M. Brecher, O. Svensson, H.M. Andersson, and D. Meulien Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study J. Clin. Psychiatry 68 2007 832 842
28. R.C. Kessler, P. Berglund, O. Demler, R. Jin, D. Koretz, K.R. Merikangas, A.J. Rush, E.E. Walters, and P.S. Wang The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA 289 2003 3095 3105
29. R.C. Kessler, C.B. Nelson, K.A. McGonagle, J. Liu, M. Swartz, and D.G. Blazer Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey Br. J. Psychiatry Suppl. 168 1996 17 30
30. R.W. Lam Sleep disturbances and depression: a challenge for antidepressants Int. Clin. Psychopharmacol. 21 Suppl 1 2006 S25 S29
31. R.W. Lam, H.F. Andersen, and A.G. Wade Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials Int. Clin. Psychopharmacol. 23 2008 181 187
32. M. Liebowitz, R.W. Lam, U. Lepola, C. Datto, D. Sweitzer, and H. Eriksson Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment of major depressive disorder (MDD): a randomized, placebo-controlled trial Depress Anxiety 27 10 2010 964 976
33. R.N. Marcus, R.D. McQuade, W.H. Carson, D. Hennicken, M. Fava, J.S. Simon, M.H. Trivedi, M.E. Thase, and R.M. Berman The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study J. Clin. Psychopharmacol. 28 2008 156 165
34. G. Mattingly, H. Ilivicky, J. Canale, and R. Anderson Quetiapine combination for treatment-resistant depression Poster NR250 presented at the American Psychiatric Association 159th Annual Meeting, Toronto, Canada, 20 - 25 May 2006
35. A. McIntyre, A. Gendron, and A. McIntyre Quetiapine adjunct to selective serotonin reuptake inhibitors (SSRIs) or venlafaxine in patients with major depression, comorbid anxiety and residual depressive symptoms: a randomized, placebo controlled pilot study Depress. Anxiety 24 2007 487 494
36. D. Michelson, M. Fava, J. Amsterdam, J. Apter, P. Londborg, R. Tamura, and R.G. Tepner Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br. J Psychiatry 176 2000 363 368
37. S.A. Montgomery Clinical measures of rapid onset of action Eur. Psychiatry 12 1997 295 300
38. S.A. Montgomery, and M. Åsberg A new depression scale designed to be sensitive to change Br. J. Psychiatry 134 1979 382 389
39. National Institutes of Mental Health CGI: Clinical Global Impressions W. Guy, R.R. Bonato, Manual for the ECDEU Assessment Battery 1970 Chevy Chase NIMH 1 6
40. G.I. Papakostas, C.H. Homberger, and M. Fava A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder J. Psychopharmacol. 22 2008 843 848
41. G.I. Papakostas, J.C. Nelson, S. Kasper, and H.J. Moller A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder Eur. Neuropsychopharmacol. 18 2008 122 127
42. K. Posner, M.A. Oquendo, M. Gould, B. Stanley, and M. Davies Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants Am. J. Psychiatry 164 2007 1035 1043
43. M. Prince, V. Patel, S. Saxena, M. Maj, J. Maselko, M.R. Phillips, and A. Rahman No health without mental health Lancet 370 2007 859 877
44. J.F. Rosenbaum, M. Fava, S.L. Hoog, R.C. Ascroft, and W.B. Krebs Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial Biol. Psychiatry 44 1998 77 87
45. A.J. Rush, M. Trivedi, and M. Fava Depression, IV: STAR*D treatment trial for depression Am. J. Psychiatry 160 2003 237
46. D.V. Sheehan, Y. Lecrubier, K.H. Sheehan, P. Amorium, J. Janavas, E. Weiller, T. Hergueta, R. Baker, and G.C. Dunbar The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J. Clin. Psychiatry 59 Suppl 20 1998 22 33
47. G.M. Simpson, and J.W.S. Angus A rating scale for extrapyramidal side effects Acta Psychiatr. Scand. Suppl. 212 1970 11 19
48. T. Suppes, C. Datto, M. Minkwitz, A. Nordenhem, C. Walker, and D. Darko Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression Poster presented at the 48th Annual New Clinical Drug Evaluation Meeting, Phoenix, Arizona, USA, May 27 - 30 2008
49. M.E. Thase, S.A. Corya, O. Osuntokun, M. Case, D.B. Henley, T.M. Sanger, S.B. Watson, and S. Dube A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder J. Clin. Psychiatry 68 2007 224 236
50. M.E. Thase, B.R. Haight, N. Richard, C.B. Rockett, M. Mitton, J.G. Modell, S. VanMeter, A.E. Harriett, and Y. Wang Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials J. Clin. Psychiatry 66 2005 974 981
51. M.E. Thase, W. Macfadden, R.H. Weisler, W. Chang, B. Paulsson, A. Khan, and J.R. Calabrese Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study) J. Clin. Psychopharmacol. 26 2006 600 609
52. M.H. Trivedi, M. Fava, S.R. Wisniewski, M.E. Thase, F. Quitkin, D. Warden, L. Ritz, A.A. Nierenberg, B.D. Lebowitz, M.M. Biggs, J.F. Luther, K. Shores-Wilson, and A.J. Rush Medication augmentation after the failure of SSRIs for depression N. Engl. J. Med. 354 2006 1243 1252
53. T.B. Ustun, J.L. Ayuso-Mateos, S. Chatterji, C. Mathers, and C.J. Murray Global burden of depressive disorders in the year 2000 Br. J. Psychiatry 184 2004 386 392
54. E.C. van Geffen, J.G. Hugtenburg, E.R. Heerdink, R.P. van Hulten, and A.C. Egberts Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation Eur. J. Clin. Pharmacol. 61 2005 303 307
55. R.H. Weisler, M. Joyce, L. McGill, A. Lazarus, J. Szamosi, and H. Eriksson Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo controlled study CNS Spectr. 14 2009 299 313
56. L.I. Yargic, A. Corapcioglu, N. Kocabasoglu, A. Erdogan, G. Koroglu, and D. Yilmaz A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety Int. J. Psychiatry Clin. Pract. 8 2004 205 211